Skip to main content
OpenTrials
Completed

NCT Number: NCT02020330

Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day

This is a randomised two arm study, comparing artemether-lumefantrine 3 days and 5 days treatment. Patients will be randomised in blocks of ten to one of the two treatment arms. The standard regimen is twice daily for three days with a delay of at least eight hours between the first and second doses. A single of primaquine will be given to all patients on the first day of treatment for gametocytocidal activity. The initial treatment will be given under supervision, all other subsequent doses will be given to the patient to the taken at home. Patients will be followed up for nine visits over forty two days.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Medical Action Myanmar

Yangon, Burma

About this study

  • The study will be conducted in 6 village health centres in the Mon and Kayin states
  • The patient or parent/guardian (in case of minor or under aged) must personally sign and date the latest approved version of the informed consent form before any study specific procedures are performed
  • A case record form will be completed for each patient documenting symptoms prior to clinic attendance, concomitant illness, drug history. Height, weight, vital signs and physical examination findings will be recorded.
  • At enrolment (D0) all patients will have the following samples taken:
  • Repeat parasite count (thick and thin films). Treatment should be started without waiting for the result.
  • Filter paper blood blots (3 dots on Whatman 3MM filter paper approx 180-300 µL blood) for parasite genotyping (MSP1, MSP2, GLURP in case of recurrence during follow-up)
  • Haemoglobin
  • Laboratory procedures
  • Slide microscopy: Thick and thin blood films stained with Giemsa will be read and counts expressed as the number of parasites per 500 white blood cells
  • Molecular studies: The samples will be used to detect asexual parasites (blood smear, sensitive PCR), parasite population structure (Sequenom genotyping and sequencing), gametocytes (microscopy). The samples will be stored in a cool box and kept maximum 5 days in the field and will be transported to the local laboratory for processing. Plasma and buffy coat will be separated, frozen and stored. The frozen packed red cells will be transported to the molecular laboratory at MORU, Bangkok, Thailand, for sample processing (DNA extraction, quantitative PCRs).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 6 year
  • Symptomatic malaria infection, i.e. history of fever or presence of fever >37.5°C
  • Microscopic confirmation of asexual stages of P. falciparum (may be mixed with non-falciparum species) with parasitaemia PFT≥5/500 WBC
  • Written informed consent given to participate in the trial

Exclusion criteria

  • Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age unless menstruating).
  • Female of 12 to 18 years of age
  • P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL).
  • Signs or symptoms indicative of severe malaria including:
  • Impaired consciousness (Blantyre Coma Score <5 or Glasgow Coma Scale <15)
  • Severe anaemia (Hb% <5 mg/dl)
  • Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites
  • Respiratory distress
  • Severe jaundice
  • Haemodynamic shock
  • A full course of artemether-lumefantrine treatment in the previous 28 days
  • Known hypersensitivity to artemisinins - defined as history of erythroderma/other severe cutaneous reaction, angioedema or anaphylaxis
  • History of splenectomy

Treatment and study plan

Artemether-lumefantrine 3 days

Drug

One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.

Other names: Coartem®, Novatis, Switzerland

Artemether-lumefantrine 5 days

Drug

One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.

Other names: Coartem®, Novartis, Switzerland

Primary outcomes

  1. proportion of patients with detectable parasitaemia

    Time frame: On day 5 and day 7

    Assessed by sensitive PCR on days 5 and 7 after treatment

Secondary outcomes

  1. Parasitaemia clearance time

    Time frame: On day 3 and Day 5

    Assessed by sensitive PCR on D3 in the 3 day arm and D5 in the 5 day arm

  2. Gametocyte carriage rates

    Time frame: Day 7

  3. artemether-lumefantrine tolerability

    Time frame: 5 days

    Tolerability of artemether-lumefantrine will be assessed by comparing the proportion of patients with anorexia, nausea, vomiting, abdominal pain and other symptoms of administration between the intervention arm and the control arm

  4. Comparison of effectiveness

    Time frame: Day 42

    Comparison of effectiveness uncorrected and corrected will be assessed by PCR genotyping

  5. concentrations of lumefantrine

    Time frame: Day 7

  6. Haematological recovery rate

    Time frame: Day 28

    Assessed by comparing hemoglobin between baseline and after treatment at day 28

  7. Incidence of vivax malaria relapses

    Time frame: 42 days

    Assessed by the microscopist find malaria smear positive within the follow up period

  8. Comparison of addition of food supplement (fish oil)

    Time frame: day 3 to day 21

    Assessed by comparing lumefantrine concentration on day 7 and proportion of patients with detectable parasitaemia by qPCR

Sponsors and collaborators

Lead sponsor

University of Oxford

Other

Registry information

Official study title

An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar

Acronym: AL3vs5

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Dec 24, 2013
Registry last updated
Sep 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.